C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta

C4 Therapeutics, Inc.

2023-Q1 EPS reported -$1.44 revenue$6,423,000

Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.
Cash, equivalents and marketable securities $286.7M as of June 30, expected to fund ops into 2H 2025.
Exclusive license for CFT8919 (EGFR L858R degrader) with Betta Pharma in Greater China: $10M upfront, $25M equity investment, up to $357M milestones plus royalties.
U.S. IND cleared for CFT8919; Phase 1/2 trials for CFT7455, CFT8634, CFT1946 ongoing; Phase 1 dose escalation data expected 2H 2023.
Appointed Len Reyno as CMO and Mary Christian as SVP Regulatory in July 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

C4 Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $2.7 million.

Period: the second quarter ended June 30, 2023
Revenue: $2.7 million
Result: reported results

Exact text from the filing

for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023. SECOND QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. The decrease in revenue was due to a reduction of revenue recognized for research activities under the Biogen and

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-027935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.